Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, provides the following trading update ahead of its preliminary results for the year ended 31 July 2016.

During the year, the Company made substantial progress and achieved a significant number of commercial, technological and organisational milestones.

Commercially, the Company took a major strategic step by moving from an exclusive to a non-exclusive model in the display market as announced on 31 March 2016, when it was also announced that Nanoco’s licence agreement with The Dow Chemical Company (“Dow”) had become non-exclusive.  The Company continues to work closely with Dow on the commercialisation of its TREVISTA™ cadmium-free quantum dots based on Nanoco’s technology and supplied from Dow’s production facility in Cheonan, South Korea.  Nanoco is in the process of transferring its improved manufacturing processes to Dow.

The Company has received notification of its royalty payment from Dow for the quarter ended 30 June 2016 and, although modest, it is higher than the first royalty received earlier this year.

The new non-exclusive commercialisation strategy has allowed the Company to open up additional routes into the display market facilitated by a substantial improvement in Nanoco’s production processes.

In July, the Company signed a supply and licence agreement with Wah Hong Industrial Corporation, a leading Taiwanese supplier of optical films to the display industry, under which Nanoco will supply resins containing cadmium-free quantum dots from Runcorn. Wah Hong has already received positive interest based on initial samples sent to its customers.  The Company recently announced a major licensing agreement with Merck KGaA, the leading German science and technology company focused on healthcare, life sciences and performance materials and the manufacturer of approximately 60 per cent of the world’s liquid crystals used in LCDs. Under the agreement, Merck will build its own large scale manufacturing plant to supply Nanoco cadmium-free quantum dots to the display market.  Ahead of Merck’s own capacity coming online, it will initiate sales with the product purchased and supplied from Nanoco’s Runcorn plant.

The Company continues to evaluate other potential commercial opportunities in the display sector.

Whilst the display sector was the primary focus of the Company during the year, the Company continued to progress its other target markets: lighting, life sciences and solar. Highlights in these markets during the year included the signing of a further joint development agreement with Osram in general lighting and the formation of a life sciences division at Nanoco to pursue opportunities in the medical devices and diagnostics markets.

This substantial progress in commercialisation and production has been accompanied by significant changes in the organisation of the business, including redeployment of staff to production, strengthening of the supply chain and some critical new hires.  Board changes during the year included the appointment of Dr Christopher Richards as Chairman and Brendan Cummins as Senior Independent Director following the resignations of Tony Clinch and Dr Peter Rowley.

Unaudited revenues in the year were £1.9 million (FY 2015: £2.0 million). The balance sheet had unaudited net cash of £14.4 million at 31 July 2016 compared with £18.3 million at 31 January 2016 (31 July 2015: £24.3 million). The aforementioned unaudited revenue and cash figures were in line with the Board’s expectations.

The Board remains confident of achieving further progress in the commercialisation of the Company’s technologies during the current financial year and beyond.

Nanoco expects to announce its preliminary results for the year ended 31 July 2016 in mid-October 2016.

This announcement contains inside information.

For further information, please contact:

Nanoco
Michael Edelman, Chief Executive Officer
David Blain, Chief Financial Officer
+ 44 (0) 161 603 7900
Caroline Watson, Investor Relations Manager
cwatson@nanocotechnologies.com
+ 44 (0) 7799 897357

Canaccord Genuity – Joint Broker
Simon Bridges
Cameron Duncan
Richard Andrews
+44 (0) 20 7523 8000

Liberum – Joint Broker
Neil Patel
Richard Bootle
Steven Tredget
+44 (0) 20 3100 2000

Buchanan
Mark Court / Sophie Cowles / Stephanie Watson
+ 44 (0) 20 7466 5000

Notes for editors:

About Nanoco Group plc

Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nanomaterials for use in multiple applications including LCD displays, lighting, solar cells and bio-imaging. In the display market, Nanoco has a non-exclusive manufacturing and marketing licensing agreements with The Dow Chemical Company, Taiwan’s Wah Hong Industrial Corporation and Merck KGaA. Nanoco also has a strategy of direct sales in display and in its other target markets, including lighting.

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development executives in Japan, Korea and Greater China. Its technology is protected worldwide by a large and growing patent estate.

Nanoco is listed on the main market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.